ERBB2 A775_G776insIVMA

CI-VAR-00000136Explore in graph →CIViC 4484

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
ERBB2 Amplification OR ERBB2 A775_G776insIVMA OR ERBB2 A775_G776insYVMA OR ERBB2 G778_P780dup OR ERBB2 G778-779 insCPG OR ERBB2 G776_V777>VCV OR ERBB2 G776delinsVC OR ERBB2 L755P OR ERBB2 V659E OR ERBB2 S310F OR ERBB2 S335C	Ado-trastuzumab Emtansine Regimen	Predictive	B	Supports Sensitivity Response	3	submitted	EID11323 In this phase II basket trial, 18 patients with advanced HER2-mutant lung adenocarcinomas were enrolled to receive ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression.… (full text at CIViC) PMID 29989854 · Li et al., 2018 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.